Biomarin Pharmaceutical (BMRN) Interest & Investment Income (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Interest & Investment Income data on file, last reported at $22.6 million in Q1 2026.

• Quarterly Interest & Investment Income rose 18.66% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.5 million (up 5.26% YoY) and the FY2025 annual result came in at $74.9 million, changed 0.03% from the prior year.
• Interest & Investment Income rose to $22.6 million in Q1 2026, from $19.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $22.6 million in Q1 2026 to a low of $1.8 million in Q1 2022.
• A 5-year average of $14.6 million and a median of $17.9 million in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 43.97% — and 2023, when it soared 556.21%.
• Tracing BMRN's Interest & Investment Income over 5 years: stood at $8.7 million in 2022, then soared by 107.16% to $18.0 million in 2023, then decreased by 2.02% to $17.7 million in 2024, then gained by 8.65% to $19.2 million in 2025, then advanced by 17.44% to $22.6 million in 2026.
• The last three Interest & Investment Income figures came in at $22.6 million (Q1 2026), $19.2 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.